Loading patent…
AssigneeKoninklijke Nederlandse Akademie van Wetenschappen
InventorsEva van Rooij, Arwa Obada Abdelrahman Reda Kohela
Estimating the term…
The present invention relates to novel treatments for treating cardiac disease involving fibro-fatty replacement, such as arrhythmogenic cardiomyopathy, atrial fibrillation, myocardial infarction and dilated cardiomyopathy. Such cardiac diseases can e.g. be caused by a mutation in a desmosomal protein such as plakophilin-2 (PKP2). The invention provides for agents for use in the prevention or treatment of such cardiac diseases, wherein the agent is at least one of: a) an agent that causes a reduction in expression in at least one TFAP2 subtype; and, b) an agent that causes a reduction in TFAP2-induced transcription. More preferably the agent is at least one of: a) an inhibitor of TFAP2; and, b) an agent that causes an increase in expression of PKP2.
-15. (canceled)
A method for treating or preventing cardiac disease wherein fibro-fatty replacement is part of the disease etiology, wherein the method comprises administering to a subject in need thereof at least one of:
An in vivo, in vitro, or ex vivo method for reducing TFAP2 expression, the method comprising the step of contacting a cell with:
A method for identifying an agent that causes at least one of a reduction in TFAP2 expression, and a reduction in TFAP2-induced transcription, the method comprising the steps of:
Dependencies are inferred from the claim text.